| Date |
Subject |
Media |
| 2025-07-29 |
CHLITINA HOLDING LIMITED’s Q2 Profit Boosted by RMB 18 Million Government Subsidy
|
CHLITINA HOLDING LIMITED (麗豐-KY) saw a significant profit boost in the second quarter, benefiting from a RMB 18 million (approximately NT$72.96 million) government subsidy recognized in its accounts. This subsidy contributed NT$0.88 to earnings per share (EPS), substantially higher than the Q1 EPS of NT$0.68. Coupled with a sales upturn in the Chinese mainland market following new product launches, analysts are optimistic about a strong quarterly profit performance, with potential for sustained momentum in the second half of the year. |
| 2025-07-29 |
Grape King Bio Maintains Full-Year Business Outlook
|
Grape King Bio reported a consolidated revenue of NT$4.82 billion for the first half of the year, a year-on-year decrease of 5.57%, due to weakened overall consumer spending. Revenue in June reached NT$880 million, representing a 6.79% increase from the previous month and remaining flat compared to the same period last year. The company anticipates that revenue in the second half will be boosted by the launch of new products, continuing its historical trend of stronger performance in the latter half of the year. All operational plans are proceeding as scheduled, and the company maintains its full-year growth target for consolidated performance. |
| 2025-07-29 |
HeXun Biosciences Reports NT$151 Million in Revenue for the First Half of the Year, Up 13.60% Year-on-Year
|
Driven by the strong momentum of its two core growth engines—CDMO/CMO clinical development and high-quality exosome raw materials—HeXun Biosciences posted revenue of NT$26.78 million in June. Cumulative revenue for the first half of the year reached NT$151 million, marking a 13.60% year-on-year increase. |
| 2025-07-29 |
Protect Biotech Targets Emerging Stock Board Listing in Early August, Focusing on Three Innovative Pet Drug Categories for Global Market Expansion
|
Protect Biotech, a company specializing in the development of new veterinary drugs, announced on July 7 that it has submitted its application earlier this month and aims to list on the Emerging Stock Board in early August. General Manager Haolin Sung stated that the company is focusing on three major categories of pet medications—cancer treatment, heart disease treatment, and autoimmune therapies. Its lead development product, PT001, which targets melanoma, is currently undergoing field trial application. Following its launch in Taiwan, the company plans to expand into international markets. |
| 2025-07-29 |
Health Supplement Industry Expands Aggressively Overseas
|
As global awareness of health and wellness continues to rise, Taiwanese health supplement companies are accelerating their expansion into international markets in search of new growth drivers. Recently, three companies—TCI Co., SHINY BRS GROUP, and Jia Jie Biomedical—have simultaneously advanced into overseas markets, launching full-scale efforts across Europe, the U.S., Japan, Southeast Asia, and Mainland China to capture international revenue growth opportunities. |
| 2025-07-29 |
TaiMed Biologics' Trogarzo Partner TH Acquired by Future Pak; TaiMed Confirms Ongoing Collaboration and Enhanced Synergy
|
TaiMed Biologics announced that its exclusive U.S. partner for the HIV drug Trogarzo, Theratechnologies (TH), has signed a definitive agreement with CB Biotechnology, an affiliate of Future Pak. Under the agreement, TH will be acquired for US$3.01 per share in cash, along with a contingent value right (CVR) of up to US$1.19 per share, bringing the total potential transaction value to US$254 million. The acquisition is expected to close in Q4 2025, pending shareholder and court approval. |
| 2025-07-29 |
KIM FOREST and Chang Hua Hospital, MOHW Collaborate to Establish Taiwan’s First “1-Ping Automated Laboratory 2.0”
|
Biotech-listed company KIM FOREST has partnered with Chang Hua Hospital, Ministry of Health and Welfare (MOHW), to successfully launch a new “Laboratory 2.0” model. The project features the implementation of Roche Diagnostics’ most advanced fully automated testing systems, creating a highly efficient and intelligent testing workflow within a limited space, and setting a new benchmark for smart healthcare in Taiwan. |
| 2025-07-29 |
Biotech M&A Heats Up: Acquiring Drug Licenses and Technologies Becomes the New Strategy—Lotus Pharm, Handa, and Taiwan Bio Therapeutics Lead the Charge
|
The wave of mergers and acquisitions in the biotech industry continues to intensify. Beyond traditional company takeovers, the acquisition of drug licenses and cutting-edge technologies—aimed at rapidly boosting revenues and enhancing R&D capabilities—has emerged as a new and increasingly strategic approach. Lotus Pharmaceutical alone acquired six drug licenses from international pharmaceutical companies in the first half of this year to expand its presence in Southeast Asia. Earlier this year, Handa Pharmaceuticals invested USD 30 million to acquire the blood cancer drug Phyrago (Dasatinib), while Taiwan Bio Therapeutics obtained the patent rights to the TregCel regulatory T cell (Treg) platform from U.S.-based TRACT for USD 3.5 million, strengthening its position in cell therapy. |
| 2025-07-29 |
Foxconn and Kawasaki Heavy Industries Testing “Nursing Robot” in Taiwan; Japanese Media: Commercial Launch Set for 2026
|
According to Nikkei Asia, Foxconn Technology and Japanese robotics giant Kawasaki Heavy Industries have jointly developed a humanoid nursing robot, which is currently undergoing testing at a hospital in Taiwan. The robot is expected to be officially launched in the Taiwanese market in fiscal year 2026, with a sales target of 200 units by fiscal year 2027. |
| 2025-07-29 |
PharmaEssentia Reports Double-Digit Growth in June Revenue; Q2 Marks Ninth Consecutive Record-High, H1 Revenue Up 73.23% Year-on-Year
|
PharmaEssentia announced that its revenue for June reached NT$1.2 billion, marking a 1.51% month-on-month increase and a 41.09% year-on-year growth. The revenue was primarily driven by steady sales growth of its novel rare blood cancer treatment, Ropeginterferon alfa-2b (Ropeg, also known as P1101), in the U.S. market. Despite the recent strength of the New Taiwan Dollar, the company still posted both monthly and yearly revenue gains, supporting continued revenue growth. |
